阿德福韦酯联合双环醇片治疗HBeAg（＋）慢性乙型肝炎疗效分析  

The analyse of effectiveness in HBeAg-positive chronic viral hepatitis B treated by adefovir dipivoxil combined with bicyclol

作　　者：相代荣[1] 盛吉芳[1] 

机构地区：[1]浙江大学医学院附属第一医院传染,杭州310003

出　　处：《中华实验和临床病毒学杂志》2009年第4期299-301,共3页Chinese Journal of Experimental and Clinical Virology

摘　　要：目的研究阿德福韦酯联合双环醇片治疗慢性乙型肝炎的疗效。方法选择91例轻、中度慢性乙型肝炎患者随机分2组接受试验。试验组，46例，每日口服阿德福韦酯10mg，同时每日服用双环醇片150mg；对照组，45例，仅给予每日口服阿德福韦酯10mg。2组均连续用药48周。观察治疗前后血清氨基转移酶水平及病毒学标志方面的改变。结果2组血清氨基转移酶均得到明显下降，试验组更为显著（P〈0．05）。试验组HBVDNA阴转率（47．8％）显著高于对照组（31．1％），P〈0．05，试验组HBeAg阴转率（32．6％）及HBeAg血清转换率（24．4％）虽高于对照组（19．6％、15．6％），但差异无统计学意义。2组均未发生明显的不良反应。结论阿德福韦酯与双环醇片联合应用治疗慢性乙型肝炎在肝功能及病毒学方面取得较好疗效。Objective To analyze the efficacy of adefovir dipivoxil combined with bicyclol in treatment of HBeAg-positive chronic viral hepatitis B （CHB）. Methods A total of 91 patients with CHB were randomized into experimental group and control group to be treated. The patients in experimental group （46 samples） received adefovir dipivoxil orally 10 mg daily and bicyclol orally 150 mg daily for 48 weeks and those in control group （45 samples） received adefovir dipivoxil orally 10 mg daily alone for 48 weeks. The serum aminotransferace （ALT/ AST）, HBV-DNA, HBeAg/antiHBe were observed before and after treatment. Results Compared with pretreatment, the serum arninotransferace were all decreased obviously in two groups, the experimental group is better （ P 〈0.05）. HBVDNA negative conversion rate was significantly higher in experimental group than in the control group（47.8% vs. 31.1%, P 〈 0.05）. There were nostatistically differrence between the two groups in the portion of HBeAg loss rate and HBeAg seroconversion rate. There were no obvious adverse reaction in the study. Conclusion Adefovir dipivoxil combined with bicyclol is elective in the treatment of chronic hepatitis B.

关 键 词：肝炎 乙型 慢性 阿德福韦酯 二环化合物 

分 类 号：R512.62[医药卫生—内科学] R512.6[医药卫生—临床医学]